您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > 3,4-dihydro Naratriptan
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
3,4-dihydro Naratriptan
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
3,4-dihydro Naratriptan图片
CAS NO:121679-20-7
包装与价格：
包装价格(元)
5mg电议
10mg电议
25mg电议

产品介绍

化学性质

Physical AppearanceA crystalline solid
StorageStore at -20°C
M.Wt333.4
Cas No.121679-20-7
FormulaC17H23N3O2S
SynonymsNaratriptan Impurity B
Solubility≤0.1mg/ml in ethanol;10mg/ml in DMSO;10mg/ml in dimethyl formamide
Chemical NameN-methyl-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)-1H-indole-5-ethanesulfonamide
Canonical SMILESO=S(CCC1=CC=C2C(C(C3=CCN(C)CC3)=CN2)=C1)(NC)=O
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

pKi: 8.9 of Naratriptan for human 5-HT1B

3,4-dihydro Naratriptan is a selective serotonin 5-HT1B agonist.

5-HT1B receptors are widely distributed throughout the CNS with the highest concentrations found in the basal ganglia, frontal cortex, striatum, and the hippocampus. The function of the 5-HT1B receptor differs depending upon its location.

In vitro: 3,4-dihydro Naratriptan is an impurity formed during the preparation of naratriptan. Naratriptan had high affinity for human recombinant 5HT1B and 5HT1D receptors and could cause contractions of dog isolated basilar and middle cerebral artery. Naratriptan also caused small contractions of human isolated coronary arteries [1].

In vivo: In anaesthetized dogs, naratriptan caused selective vasoconstriction of the carotid arterial bed and, in anaesthetized rats, naratriptan selectively inhibited neurogenic plasma protein extravasation in the dura. In various antinociceptive tests, naratriptan had no effect even at high doses. In conscious rats and dogs, naratriptan had high oral bioavailability [1].

Clinical trial: Naratriptan has been approved for acute oral migraine therapy. In two Phase III trials of naratriptan compared with placebo, relief at four hours was obtained in 60% and 68% of patients using the 2.5-mg dose, with recurrence of headache in 24 hours in 27% and 28% of patients. Adverse effects of naratriptan were found to be similar to placebo, and its tolerability appeared superior compared with studies of other oral triptans [2].

References:
[1] Connor HE, Feniuk W, Beattie DT, North PC, Oxford AW, Saynor DA, Humphrey PP.  Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia. 1997 May;17(3):145-52.
[2] Dulli DA.  Naratriptan: an alternative for migraine. Ann Pharmacother. 1999 Jun;33(6):704-11.